A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

June 16, 2016

Primary Completion Date

January 16, 2023

Study Completion Date

January 16, 2023

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Decitabine

DRUG

BI 836858

Trial Locations (14)

10967

Vivantes Netzwerk für Gesundheit GmbH, Berlin

11042

Northwell Health, Lake Success

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

25123

A.O. Spedali Civili di Brescia, Brescia

32224

Mayo Clinic Cancer Center, Jacksonville

43210

The Ohio State University Wexner Medical Center, Columbus

46026

Hospital Politècnic La Fe, Valencia

48149

Universitätsklinikum Münster, Münster

60611

Northwestern University, Chicago

86156

Universitätsklinikum Augsburg, Augsburg

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

07740

Universitätsklinikum Jena, Jena

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY